Is Imunon, Inc. (IMNN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.3% / 30% | 53.3% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 10.3% / 33% | 53.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 11.7% / 33% | 60.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 10.3% / 33% | 53.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 11.7% / 33% | 60.4% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -233.5% | |
| Return on Assets (ROA) | -77.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$19M |
| Free Cash Flow | -$19M |
| Total Debt | $1M |
| Debt-to-Equity | 27.0 |
| Current Ratio | 1.7 |
| Total Assets | $10M |
Price & Trading
| Last Close | $2.71 |
| 50-Day MA | $3.22 |
| 200-Day MA | $5.39 |
| Avg Volume | 45K |
| Beta | 2.2 |
|
52-Week Range
$2.52
| |
About Imunon, Inc. (IMNN)
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Imunon, Inc. (IMNN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Imunon, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Imunon, Inc.'s debt ratio?
Imunon, Inc.'s debt ratio is 10.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.7%.
What are Imunon, Inc.'s key financial metrics?
Imunon, Inc. has a market capitalization of $9M. Return on equity stands at -233.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.